P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters

Arık, Deniz; Kulaçoğlu, Sezer

doi:10.5146/tjpath.2010.01045

Cited by 7 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…from 29 to 40.7% [1,5,6,7,8,9,12,13], and a small number of studies showed higher rates of CIN2/CIN3 for LSIL/ASC-H, i.e. from 45 to 61% [2,3,4]. Our result was 43%, which is consistent with the former results.…”

Section: Discussionsupporting

confidence: 82%

“…In line with these studies, our results support that the current clinical practice is valid (management is the same for ASC-H) [3,4,6,9,13]. …”

Section: Discussionsupporting

confidence: 80%

“…Alsharif et al [9] and Işık et al [3] discussed these differences in their reports, yet other authors did not evaluated the number of CIN2 and CIN3 separately; instead they combined them in the HSIL group. Therefore, we cannot determine the actual CIN2 and CIN3 detection rates of LSIL/ASC-H from these nonseparated reports.…”

Section: Discussionmentioning

confidence: 93%

“…Such cases are referred to as SILs of indeterminate grade in the TBS 2001 manual, but there was not a specific diagnostic category including the cervical smears which exhibit LSIL and ASC-H cytomorphology in the abbreviated versions of TBS 2001 [10,11]. There have been a number of studies focusing on this subset of cases, and many authors believe LSIL/ASC-H should be considered as a distinct diagnostic category [2,3,4,5,6,7,8] in TBS.…”

Section: Discussionmentioning

confidence: 99%

“…These cases typically contain numerous cells of LSIL and only a few cells with features suggesting HSIL. There is a great deal of published literature on how well a finding of LSIL/ASC-H cytology predicts HSIL on subsequent histological examination [1,2,3,4,5,6,7,8]. Nearly all of the articles recommend that LSIL/ASC-H be a separate category in TBS and that a follow-up colposcopy should be performed clinically for all of these patients.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Is the Low-Grade Squamous Intraepithelial Lesion/Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion Category Associated with Cervical Intraepithelial Neoplasia 2?

Çetiner

Kır²,

Kaygusuz³

et al. 2013

Acta Cytologica

View full text Add to dashboard Cite

Objective: A number of cervical smears may exhibit unequivocal low-grade squamous intraepithelial lesions (LSIL) in association with atypical cells cytomorphologically suspicious, but not sufficient to be interpreted as high-grade squamous intraepithelial lesions (HSIL). These lesions are presently called LSIL, atypical squamous cells cannot exclude HSIL (LSIL/ASC-H). Previous studies have shown that LSIL/ASC-H and ASC-H are both equivocal for HSIL and have a high risk of underlying HSIL. However, in researching the literature only two studies were found which rendered the results as cervical intraepithelial neoplasia (CIN) 2 and CIN3 separately. The purpose of this study was to compare the distribution of biopsy results for CIN2 and CIN3 in patients with ASC-H, HSIL, and LSIL/ASC-H. Study Design: Between January 2005 and December 2011, cervicovaginal smears (98,594) with a diagnosis of ASC-H, LSIL, LSIL/ASC-H, or HSIL were re-evaluated to determine the prevalence of future lesion development. Results: A total of 252 patients who had histologic follow-up within a year were selected. Among these, LSIL/ASC-H (31.7%) had the highest prevalence of CIN2 between LSIL (9.3%), ASC-H (10%), and HSIL (16%). All differences were statistically significant. Conclusion: Because of the high predictive value of CIN2, LSIL/ASC-H may have further importance, especially in women of different age groups.

show abstract

Section: Discussionsupporting

confidence: 82%

“…In line with these studies, our results support that the current clinical practice is valid (management is the same for ASC-H) [3,4,6,9,13]. …”

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Is the Low-Grade Squamous Intraepithelial Lesion/Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion Category Associated with Cervical Intraepithelial Neoplasia 2?

Çetiner

Kır²,

Kaygusuz³

et al. 2013

Acta Cytologica

View full text Add to dashboard Cite

show abstract

Clinicopathological and prognostic significance of NM23 expression in patients with non-small cell lung cancer

Min

Zheng

2021

Medicine

View full text Add to dashboard Cite

Background: There is a heated debate on the clinicopathological features and prognostic significance with non-metastasis 23 (NM23) expression in patients with non-small cell lung cancer (NSCLC). Thus, we conducted this meta-analysis to evaluate the clinicopathological features and prognostic significance of NM23 for NSCLC patients.Methods: Pubmed, Embase, and Web of Science were exhaustively searched to identify relevant studies published prior to March, 2020. Odds radios (ORs) and hazard radios with 95% confidence intervals (CIs) were calculated to summarize the statistics of clinicopathological and prognostic assessments. Q-test and I 2 -statistic were utilized to assess heterogeneity across the included studies. We also performed subgroup analyses and meta-regression analyses to identify the source of heterogeneity. Publication bias was detected by Begg and Egger tests. Sensitivity analysis was used to value the stability of our results. All the data were analyzed using statistical packages implemented in R version 4.0.5.Results: Data from a total of 3170 patients from 36 studies were extracted. The meta-analysis revealed that low expression of NM23 was correlated with higher risk of NSCLC (OR = 4.35; 95% CI: 2.76-6.85; P < .01), poorer tumor node metastasis (TNM) staging (OR = 1.39; 95% CI: 1.01-1.90; P = .04), poorer differentiation degree (OR = 1.37; 95% CI: 1.01-1.86; P = .04), positive lymph node metastasis (OR = 1.83; 95% CI: 1.22-2.74; P < .01), lung adenocarcinoma (OR = 1.45; 95% CI: 1.20-1.75; P < .01), and poorer 5-year overall survival (OS) rate (hazard radio = 2.33; 95%CI: 1.32-4.11; P < .01). The subgroup analyses and metaregression analyses suggested that the "Publication year", "Country", "Sample size", and "Cutoff value" might be the source of heterogeneity in TNM staging, differentiation degree, and lymph node metastasis. Both Begg test and Egger test verified that there were publication bias in 5-year OS rate. Sensitivity analysis supported the credibility of the results. Conclusion:The reduced NM23 expression is strongly associated with higher risk of NSCLC, higher TNM staging, poorer differentiation degree, positive lymph node metastasis, lung adenocarcinoma, and poorer 5-year OS rate in NSCLC patients, which indicated that NM23 could serve as a biomarker predicating the clinicopathological and prognostic significance of NSCLC. Abbreviations: CI = confidence interval, EMT = epithelial-mesenchymal transition, HR = hazard radio, IHC = immunohistochemistry, LOH = loss of heterozygosity, LUAD = lung adenocarcinoma, NDPK = nucleoside diphosphate kinase, NM23 = non-metastasis 23, NSCLC = non-small cell lung cancer, OR = odds radio, OS = overall survival, PEDro = Physiotherapy Evidence Database, RCT = randomized controlled trial, RoB = risk of bias.

show abstract

Expression of CUE domain containing 2 protein in serous ovarian cancer tissue: predicting disease-free and overall survival of patients

et al. 2020

J Int Med Res

View full text Add to dashboard Cite

Objective The aim of this study was to predict disease-free (DFS) and overall (OS) survival of cancer patients through expression of CUE domain containing 2 (CUEDC2) protein. Methods In this retrospective study, we investigated CUEDC2 expression in 75 serous ovarian cancer tissues and 34 tubal fimbria tissues by immunohistochemistry. Chemoresistance was analyzed using clinical follow-up data. Results CUEDC2 expression scores were 1.35 ± 0.60, 1.54 ± 0.57, 1.78 ± 0.71, and 2.13 ± 0.27 for International Federation of Gynecology and Obstetrics (FIGO) stages I, II, III, and IV tissues, respectively, indicating that CUEDC2 expression increased with stage and that scores differed between patients with early and advanced cancers. We found no differences in CUEDC2 expression for tissues with low, medium, and high differentiation. CUEDC2 expression was unrelated to patient age, pathological grade, or presence or absence of lymph node metastasis, but was related to tumor stage. For CUEDC2-positive patients, median DFS and OS survival were 32.6 and 54.3 months, respectively. For CUEDC2-negative patients, median DFS and OS were 51.9 and 63.5 months, respectively. Expression of CUEDC2 was correlated with DFS but not OS. Conclusion CUEDC2 is highly expressed in ovarian cancer tissues and is related to tumor stage and DFS.

show abstract

P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters

Cited by 7 publications

References 28 publications

Is the Low-Grade Squamous Intraepithelial Lesion/Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion Category Associated with Cervical Intraepithelial Neoplasia 2?

Is the Low-Grade Squamous Intraepithelial Lesion/Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion Category Associated with Cervical Intraepithelial Neoplasia 2?

Clinicopathological and prognostic significance of NM23 expression in patients with non-small cell lung cancer

Expression of CUE domain containing 2 protein in serous ovarian cancer tissue: predicting disease-free and overall survival of patients

Contact Info

Product

Resources

About